177Lu-PSMA-617放射性配体治疗反应不足后加用225Ac-PSMA-617治疗mCRPC:前瞻性登记研究(REALITY研究)的疗效与安全性评估
该前瞻性登记研究纳入51例接受177Lu-PSMA-617单药治疗后反应不足的mCRPC患者,随后启动225Ac-PSMA-617加量治疗。结果显示24/51例(47.1%)达部分缓解,中位无进展生存期6.3个月、总生存期9.1个月,多数CTCAE分级保持稳定,严重不良事件罕见,未见因副作用终止治疗。
要点
- 225Ac-PSMA-617加量后47.1%患者达部分缓解,31.4%疾病稳定,21.6%疾病进展。
- 中位无进展生存期6.3个月,中位总生存期9.1个月。
- 多数CTCAE分级保持稳定,严重不良事件罕见,无因副作用终止治疗。
核心结论
- 225Ac-PSMA-617加量177Lu-PSMA-617放射性配体治疗在常规177Lu-PSMA-617治疗失败后的患者中似乎是一种有效的升级治疗选择,在抗肿瘤效应与可耐受副作用之间具有前景。
研究设计与样本
- 前瞻性登记研究(REALITY研究),纳入51例接受177Lu-PSMA-617单药治疗后反应不足的mCRPC患者,随后启动225Ac-PSMA-617加量治疗,活度根据个体患者特征调整。
主要发现
- 启动225Ac-PSMA-617加量后,24/51例(47.1%)达部分缓解,16/51例(31.4%)疾病稳定,11/51例(21.6%)疾病进展。
- 中位无进展生存期为6.3个月,中位总生存期为9.1个月。
- 启动加量后多数CTCAE分级保持稳定,严重不良事件罕见,未见因副作用终止治疗。
关键数值与推荐
- 不良事件依据常见不良事件评价标准(CTCAE v.5.0)评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Even though the introduction of 177 Lu-PSMA-617 RLT represents a major milestone in the treatment of mCRPC, there are still patients who do not respond adequately to this therapy and for whom there are only limited options left. Augmenting 177 Lu-PSMA-617 RLT with the alpha-emitter 225 Ac-PSMA-617 may present an escalating treatment option to increase efficacy. In this study, we aim to evaluate outcome and safety of 225 Ac-PSMA-617 augmentation to 177 Lu-PSMA-617 RLT in patients who present insufficient response to monotherapy with 177 Lu-PSMA-617 RLT. PATIENTS AND METHODS: The study included n = 51 mCRPC patients enrolled in a prospective registry receiving 177 Lu-PSMA-617 monotherapy and showing insufficient response, followed by initiation of 225 Ac-PSMA-617 augmentation, with adjusted activities depending on individual patient characteristics. Biochemical response, progression-free survival, and overall survival were assessed. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0). RESULTS: After initiation of 225 Ac-PSMA-617 augmentation to 177 Lu-PSMA-617 RLT, 24/51 patients (47.1%) exhibited partial remission, 16/51 (31.4%) stable disease, and 11/51 (21.6%) progressive disease. The median progression-free survival and overall survival rates were 6.3 months and 9.1 months, respectively. The majority of CTCAE gradings remained stable after initiating augmentation. Severe adverse events were rare, and no treatment termination due to side effects was recorded. CONCLUSIONS: 225 Ac-PSMA-617 augmented 177 Lu-PSMA-617 radioligand therapy seems to be an effective escalating treatment option in patients after failure of conventional 177 Lu-PSMA-617 RLT and represents a promising approach balancing antitumor effect and tolerable side effects.
引用
- Rosar F, Khreish F, Nagel LS, et al. 225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study). Clin Nucl Med. 2024. PMID: 39787407. doi:10.1097/RLU.0000000000005640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。